Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Amivantamab, Lazertinib and Pemetrexed in First-line EGFR-mutated Advanced NSCLC
NCT05299125Phase 2Completed
- Sponsor
- Latin American Cooperative Oncology Group
- Start
- May 2023
- Primary completion
- Aug 2024
- Modality
- Fragment-Derived Small Molecules, Bispecific Antibodies, Orthosteric Ligands
- Countries
- 1
01
Overview
A Phase 2 trial of amivantamab, lazertinib in non-small cell lung cancer (NSCLC), sponsored by Latin American Cooperative Oncology Group. Started May 2023; status: completed.
02
Drugs
amivantamablazertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05299125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05299125.